Good Governance for Medicines in Jordan


Published on

Presentation by the Director General, Jordan Food and Drug Administration (JFDA) on ' Good Governance for Medicines in Jordan', during the World Health Assembly (WHA) in Geneva, 19 May 2009.

Published in: Health & Medicine, Business
1 Like
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • Good Governance for Medicines in Jordan

    1. 1. Good Governance for Medicines in Jordan Prof. Mohammad Rawashdeh JFDA Director General
    2. 2. JORDAN 10/06/09 MeTA <ul><li>• Jordan is a low middle – income country </li></ul><ul><li>Population in millions: 5,894,960 </li></ul><ul><li>10.4 % of the Jordanian GDP is spent on health with one third of this spent on medicinal drugs. </li></ul><ul><li>One quarter of the drug expenditure is spent in the public sector with the remaining three quarter spent in the private sector. </li></ul><ul><li>Medicines expenditure growth 17% per annum compared to GDP growth of 3.3%. </li></ul>
    3. 3. The problem of corruption “ The abuse of entrusted power for personal gain” <ul><li>• Globally more than US$ 4.4 trillion is spent on health services each year. The value of the global pharmaceutical market is estimated at over US$ 600 billion. </li></ul><ul><li>• 10-25% of public procurement on medicine is lost because of corruption and bad governance. </li></ul><ul><li>• Corruption is a global scourge not confined to a certain culture or country, it exists in developing and developed countries, as it exists in the public and private sectors and in different strata of society. </li></ul><ul><li>• Corruption identified as the most important obstacle in the process of economic and social development. </li></ul>
    4. 4. Efforts to address corruption need coordinated application of two basic strategies <ul><li>1. &quot;Discipline-based approach&quot; (top-down): </li></ul><ul><ul><li>- Laws, policies and procedures against corruption and for pharmacy practice with adequate punitive consequence for violation </li></ul></ul><ul><ul><li>- Attempts to prevent corrupt practices through fear of punishment </li></ul></ul><ul><li>2 . &quot; Values-based approach&quot; (bottom-up) </li></ul><ul><ul><li>- Promotes institutional integrity through promotion moral values and ethical principles </li></ul></ul><ul><ul><li>- Attempts to motivate ethical conduct of public servant </li></ul></ul>
    5. 5. Good Governance for Medicines programme <ul><li>• The goal of GGM Programme is to improve the situation of medicines regulation and supply. </li></ul><ul><li>• The programme is raising awareness of potential abuse in the public pharmaceutical sector and promoting good governance. </li></ul><ul><li>• Its ultimate aim is to ensure that essential medicines reach the people who need them. </li></ul><ul><li>• Jordan join the program in 2007, which was established by WHO in 2004. </li></ul>
    6. 6. PHASE II Development national GGM framework PHASE III Implementation national GGM programme PHASE I National transparency assessment Assessment report GGM framework officially adopted GGM Strategic Plan of Action Good Governance for Medicines programme: a model process Clearance MOH
    7. 7. Assessment of transparency and accountability <ul><li>• Assesses vulnerability to corruption of systems in place </li></ul><ul><li>• Looks at key functions of the pharmaceutical sector systems </li></ul><ul><ul><li>- Regulation: registration, inspection, promotion </li></ul></ul><ul><ul><li>Supply: selection, procurement, distribution </li></ul></ul><ul><li>• Elements evaluated: </li></ul><ul><ul><li>- Country's regulations and official documents </li></ul></ul><ul><ul><li>- Written procedures and decision-making processes </li></ul></ul><ul><ul><li>- Committees, criteria for membership and conflict of interest policy </li></ul></ul><ul><ul><li>- Appeals mechanisms and other monitoring systems </li></ul></ul>PHASE II PHASE I PHASE III
    8. 8. Assessment of transparency in Jordan <ul><li>• Assessment was conducted in October - November /2007, Assessment report was published and disseminated in January 2009 </li></ul><ul><li>• The results of the assessment and recommendations were disseminated to the stakeholders through a national workshop in february/2008 </li></ul><ul><li>• Two committees have been nominated : GGM Steering Committee, and Task Force Committee </li></ul><ul><li>• Some improvements occurred in the procedures of the pharmaceutical sector </li></ul>PHASE II PHASE I PHASE III
    9. 9. Areas of Improvement - Conflict of interest policy - Audit results publicly available Procurement - Conflict of interest policy - Selection criteria for members Selection - Conflict of interest policy - Clear criteria for selection of inspectors Inspection - Complete provisions to cover all Activities related to drug promotion Promotion - Conflict of interest policy - Committee composition & TOR <ul><li>Registration </li></ul>
    10. 10. GGM Steering Committee <ul><li>• Members are high level policy makers </li></ul><ul><li>• Responsible for the overall management, adoption and evaluation of the GGM programme </li></ul><ul><li>• Ensure implementation of recommendations made in assessment report </li></ul><ul><li>• Ensure that the national Framework for Good Governance in the public pharmaceutical sector is officially adopted </li></ul><ul><li>• Ensure the establishment of policies and procedures for the control of reprehensible acts </li></ul><ul><li>• Ensure the establishment of a whistle-blowing mechanism </li></ul><ul><li>• Ensures the establishment and implementation of a GGM programme (phase III) </li></ul>
    11. 11. GGM Task Force <ul><li>The GGM Task Force main tasks include: </li></ul><ul><li>1. Manage the national consultations process necessary to: </li></ul><ul><li>a. Share the results of the national assessments of transparency and vulnerability to corruption in the public pharmaceutical sector and </li></ul><ul><li>b. Develop and implement the national GGM framework that approved by the steering committee </li></ul><ul><li>2. Follow-up and act upon the recommendations made in the national assessments report and by the steering committee. </li></ul><ul><li>3. Coordinate the development, adoption, and socializing the national ethical framework and the code of conduct </li></ul>
    12. 12. Jordan GGM Framework Partnership <ul><li>• Ministry of Health. </li></ul><ul><li>• Ministry of Public Sector Development. </li></ul><ul><li>• Jordan Food & Drug Administration. </li></ul><ul><li>• Anti Corruption Commission. </li></ul><ul><li>• Royal Medical Services. </li></ul><ul><li>• High Health Council. </li></ul><ul><li>• Joint Procurement Department. </li></ul><ul><li>• Jordan University Hospital. </li></ul><ul><li>• World Health Organization. </li></ul>
    13. 13. Components for National GGM Frameworks <ul><li>• Ethical framework of moral values & ethical principles </li></ul><ul><ul><li>- Justice/fairness </li></ul></ul><ul><ul><li>- Truth </li></ul></ul><ul><ul><li>- Service to common good </li></ul></ul><ul><ul><li>- Trusteeship </li></ul></ul><ul><li>• Code of conduct </li></ul><ul><li>• Socialization programme </li></ul><ul><li>• Promotion of Moral Leadership </li></ul>• Established anti-corruption legislation • Whistle-blowing mechanism • Sanctions on reprehensible acts • Transparent and accountable regulations and administrative procedures • Collaboration with other GG & AC initiatives • Management, coordination and evaluation of GGM programme (Steering Committee & Task Force) Discipline based approach Values based approach PHASE II PHASE I PHASE III
    14. 14. Implementation of National GGM Programme <ul><li>• It is the phase of implementation the national program of good governance and institutionalizing it in the public pharmaceutical sector. </li></ul><ul><li>• This phase aims to promote the framework among key pharmaceutical actors and to translate its recommendations into action through a set of strategic activities increasing awareness, strengthening integrity systems and building capabilities for leadership. </li></ul><ul><li>• Jordan now is considered in this phase. </li></ul>PHASE II PHASE I PHASE III
    15. 15. Suggested Activities in Jordan for Phase III <ul><li>• Training of the national GGM team, briefing sessions for government officials, production of advocacy materials. </li></ul><ul><li>• Changing some procedures in the public pharmaceutical sector to make them more transparent. </li></ul><ul><li>• Adoption of a code of conduct for pharmacist in the public sector. </li></ul><ul><li>• Development of a COI guidelines </li></ul><ul><li>• Introducing the GGM concept into university curricula. </li></ul>
    16. 16. Progress <ul><li>• In January 2009 a Phase III training workshop was held for the first time in Jordan. It focused on anti-corruption & pharmaceutical sector legal frameworks, implementation of the recommendations included in the transparency assessment (Phase I) & moral leadership capabilities. </li></ul><ul><li>• Among 26 countries globally including 5 countries in EMR, 10 countries are in phase I, 11 countries in phase II and 5 in phase III including Jordan. </li></ul><ul><li>• Jordan recently finalized the national GGM framework, and is the 1 st EMR country to enter the implementation phase ( phase III). . </li></ul>